EQS-News
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
- U.S. antitrust clearance received for Novartis acquisition of MorphoSys.
- Novartis to offer €68.00 per share in cash for MorphoSys.
- Closing of the Takeover Offer expected in first half of 2024.
EQS-News: MorphoSys AG / Key word(s): Miscellaneous Media Release |
Planegg/Munich, Germany, March 22, 2024
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) in connection with the
proposed acquisition of MorphoSys by Novartis AG (“Novartis”), following the expiration of the HSR Act waiting period. MorphoSys previously also announced the receipt of antitrust clearance in
Germany and Austria. As a result, the proposed acquisition of MorphoSys by Novartis has now received all mandatory regulatory approvals.
On February 5, 2024, MorphoSys announced the intention of Novartis to submit a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares at an offer price of € 68.00
per share in cash (the “Takeover Offer”), representing a total equity value of € 2.7 billion. The offer document of the Takeover Offer is expected to be published by Novartis in April 2024 in
accordance with the provisions of the German Securities Acquisition and Takeover Act, after the German Federal Financial Supervisory Authority (“BaFin”) has approved the publication. Once the offer
document is published by Novartis, the acceptance period for MorphoSys shareholders to tender their shares will begin. The Takeover Offer will require a minimum acceptance threshold of 65% of
MorphoSys’ share capital, among other customary closing conditions.
MorphoSys and Novartis continue to expect the closing of the Takeover Offer to take place in the first half of 2024.
About MorphoSys
At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to
redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter at X and LinkedIn.